Oscar Calsamiglia

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.